| |||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
NADH deficiency is known to occur only in the presence of vitamin B3 deficiency, which is rare in Western society except in some alcoholics.
NADH appears to be a chemically unstable molecule that decomposes rapidly. For this reason, techniques have been developed to stabilize the NADH sold in tablet form. At the present time, it is not known which commercially available NADH products are most effective.
Researchers have used 10 mg per day, taken with water only, on an empty stomach.
Clinical studies of NADH using oral or intravenous administration have reported no side effects with up to one year or more of use. Longer-term use has not been evaluated.
At the time of writing, there were no well-known drug interactions with NADH.
1. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson’s disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 1996;103:1187–93.
2. Birkmayer W, Birkmayer JGD, Vrecko K, et al. The clinical benefit of NADH as stimulator of endogenous L-Dopa biosynthesis in Parkinsonian patients. In: Streifler MB, Korczyn AD, Melamed E, et al. (eds). Advances in Neurology, vol. 53 (Parkinsons Disease: Anatomy, Pathology, and Therapy). New York: Raven Press, 1990, 545–9.
3. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)— a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand Supp 1993;146:32–5.
4. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson’s disease with NADH. Acta Neurol Scand 1994;90:345–7.
5. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996;26:1–9.
6. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent: experience with 205 patients. New Trends Clin Neuropharmacol 1991;5:19–25.
7. Forsyth LM, MacDowell-Carnciro AL, Birkmayer GD, et al. The use of NADH as a new therapeutic approach in chronic fatigue syndrome. Presented at the annual meeting of the American College of Allergy, Asthma & Immunology, 1998.
| |||||||